Employees: 103
Size Alector (ALEC) is a United States Health Care company (Biotechnology) with a market value of $383M, the 2864th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.57 on 18 Nov 2026.
Performance Over six months the shares gained 21.2%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 151.2% over the last twelve months (peer median +5.5%); the operating margin is 24.6% (peer median -4.3%).
Valuation It trades at 1.5× enterprise value to sales against a peer median of 5.2× (3rd cheapest of 16).
Short interest Short interest is 5.6% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $173M | $21.0M | $101M | $97.1M | $134M |
| Revenue growth | — | -79% | +4% | -27% | — |
| Gross profit | $165M | $11.4M | $91.7M | $88.2M | $125M |
| EBITDA | $51.1M | -$136M | -$134M | -$143M | -$129M |
| Net income | $41.4M | -$143M | -$119M | -$130M | -$133M |
| Free cash flow | -$150M | -$184M | -$231M | -$187M | -$24.4M |
| Capital expenditure | $149,000 | $41,000 | $1.25M | $2.38M | $4.12M |
| Total debt | $21.0M | $36.2M | $42.5M | $38.9M | $43.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALEC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.5% | -13.7% | highest of 21 |
| 6-month return | +21.2% | -31.0% | highest of 21 |
| Distance from 52-week high | -9.5% | -47.6% | highest of 21 |
| Revenue growth (TTM) | +151.2% | +5.5% | 4th highest of 16 |
| Operating margin | 24.6% | -4.3% | 5th highest of 16 |
| EV / Sales | 1.5× | 5.2× | 3rd cheapest of 16 |
| EV / EBITDA | 5.2× | 20.7× | 3rd cheapest of 6 |
| Net debt / EBITDA | -2.3× | -2.6× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |